fulvestrant (Faslodex)

Tradename: Faslodex Indications: 1) metastatic breast cancer 2) postmenopausal women with cancer progression on tamoxifen Dosage: monthly IM injections Adverse effects: 1) injection site reaction 2) similar to other estrogen receptor antagonists a) hot flashes b) nausea Mechanism of action: -> estrogen receptor antagonist Notes: Manufacturer: AstraZeneca

General

antineoplastic endocrine agent estrogen antagonist

References

Prescriber's Letter 9(6):35 2002